Biotech Industry · us
PTC Takes Over Fabry Gene Therapy in Potential $211 Million Deal as ST-920 Nears Filing Finish Line
Sangamo’s single-dose AAV therapy has already had portions of its U.S. marketing application submitted; PTC is betting not only on early clinical signals, but also on whether the manufacturing documentation can be completed in the fourth quarter and clear the most challenging regulatory hurdle for gene therapies.
A rare disease gene therapy that has reached the marketing application stage has found a new owner following an asset auction. PTC Therapeutics will acquire Sangamo Therapeutics’ Fabry disease therapy ST-920 for an upfront payment of $111 million and up to $100 million in milestone payments based on subsequent progress. If the transaction and filing advance smoothly, the asset could rapidly expand PTC’s rare disease product portfolio.
ST-920, also known as isaralgagene civaparvovec, uses an AAV2/6 vector carrying the human α-galactosidase A gene. Through a single intravenous infusion, it enables patients’ bodies to continuously produce the enzyme they lack. Fabry disease is an inherited lysosomal storage disorder; insufficient enzyme function causes lipid metabolites to accumulate progressively and may damage the kidneys, heart, and nervous system over time.
PTC said ST-920 is being submitted to the U.S. Food and Drug Administration through a rolling Biologics License Application. The nonclinical and clinical modules have already been submitted, while the remaining chemistry, manufacturing, and controls information is expected to be completed in the fourth quarter. This places much of the transaction’s near-term value on execution of the filing: although the asset is approaching the end of the regulatory process, it must still demonstrate manufacturing process consistency, quality control, and commercial production capability.
The STAAR Phase 1/2 trial supporting the application is a global, multicenter, open-label, dose-finding study. ClinicalTrials.gov registration data show that the study enrolled 36 patients with Fabry disease and evaluated ST-920 as a single intravenous infusion; both the primary study and the overall study were completed on April 10, 2025. The therapy is designed to establish a stable, long-term source of α-galactosidase A rather than rely on repeated enzyme replacement.
However, the trial’s small size, lack of randomized controls, and use of different doses across groups limit the certainty of efficacy comparisons. Even if enzyme activity, disease-related metabolites, or organ indicators show signs of improvement, long-term clinical benefit cannot be confirmed from this type of early-stage study alone. The durability of AAV therapy, delayed safety risks, and the potential effects of patients’ pre-existing antibodies still require longer follow-up.
The transaction, worth up to $211 million, therefore is not simply the purchase of a clinical candidate, but the takeover of a development program that has entered its final manufacturing and regulatory push. Whether the manufacturing module is submitted on schedule in the fourth quarter, whether the FDA accepts the complete application, and the results of subsequent facility inspections and quality reviews will determine whether PTC can turn its winning auction bid into a single-dose Fabry disease treatment that can actually reach the market.